A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

Yui Takeshige(Showa University), Akira Nishiyama(Kagawa University)
Hypertension Research
January 28, 2016
Cited by 58


Related Papers